WuXi partnerships at risk as lawmakers target Chinese ties to biopharma
PharmaVoice
by Amy Baxter
2d ago
Why the legislation could throw a wrench into the supply chain for advanced therapies and how the industry has responded ..read more
Visit website
Vistagen’s on-demand nasal spray could provide a novel option for social anxiety
PharmaVoice
by Kelly Bilodeau
2d ago
The fast-acting medication is one of a few new approaches being tested for the crippling condition ..read more
Visit website
Roivant spinoff tackles growing complexity of clinical trials
PharmaVoice
by Kelly Bilodeau
4d ago
As precision medicine booms, all trials are starting to look like rare disease trials, the company said ..read more
Visit website
3 patent expirations in 2024 and how companies are pivoting
PharmaVoice
by Amy Baxter
1w ago
As the cliffs approach, pharma companies are tackling the sales hit with diverging strategies ..read more
Visit website
Ukraine was pharma’s ‘darling’ of clinical trials. As war drags on, will the industry come back?
PharmaVoice
by Meagan Parrish
1w ago
New clinical trial starts are picking back up, but are still far below their bustling pre-war level.  ..read more
Visit website
Where the GLP-1 weight loss market goes will depend on data
PharmaVoice
by Amy Baxter
1w ago
As GLP-1s expand into new disease categories, their impact could be enough to overtake leading cardiovascular drugs ..read more
Visit website
Traditional gene therapies are uber-niche. Ocugen hopes to change that.
PharmaVoice
by Alexandra Pecci
1w ago
The biotech is developing a ‘gene-agnostic’ approach to expand the patient pool for gene therapies ..read more
Visit website
3 big recent trial flops
PharmaVoice
by Meagan Parrish
1w ago
How these clinical setbacks impacted the companies, industry and patients ..read more
Visit website
How pharma’s surging M&A is impacting the industry’s tech sector
PharmaVoice
by Michael Gibney
1w ago
As dealmaking in biopharma picks up, the CEO of eClinical Solutions sees an opportunity for clinical software companies to make acquisitions easier to close ..read more
Visit website
Psychiatry drugs finally have pharma’s attention. Can they keep it?
PharmaVoice
by Jacob Bell
2w ago
Recent biotech company acquisitions have put emerging schizophrenia treatments in focus. But many development hurdles still stand in the way of new medicines for the brain ..read more
Visit website

Follow PharmaVoice on FeedSpot

Continue with Google
Continue with Apple
OR